Found 14 matching trials
An Extension of Istradefylline in Parkinson's Disease Patients Who Have Completed Studies 6002-EU-007, 6002-US-013 or 6002-US-018
PHASE3This is a 1-year, open-label, long-term safety extension for patients who h...
Location
Kyowa Pharmaceutical Inc.
A Study of Istradefylline (KW-6002) for the Treatment of Parkinson's Disease
PHASE3The purpose of this study is to evaluate the efficacy of 40 mg a day of ist...
Location
Kyowa Hakko UK Ltd.
A Study of Istradefylline (KW-6002) in Treating Patients With Parkinson's Disease on Levodopa
PHASE3To establish the efficacy of 10, 20 and 40 mg/d dose of istradefylline for ...
Location
Kyowa Pharmaceutical Inc.
Effect of Mild Hepatic Impairment on the Pharmacokinetics of Istradefylline
PHASE1The purpose of this study is to test whether mild liver impairment affects ...
Location
Orlando Clinical Research Center
Istradefylline Effect Protocol on Parkinson's Disease Tremor
PHASE4This is an investigator-initiated trial. In this 6-month open label, single...
Location
Georgetown University Hospital
Study of KW-6002 (Istradefylline) in Parkinson's Disease in Patients With Motor Response Complications on Levodopa
PHASE3The purpose of this study is to confirm the long term tolerability and safe...
Location
The University of Chicago
Long-Term Safety Study of KW-6002 (Istradefylline) in Parkinson's Disease Patients
PHASE3Patients with Parkinson's disease who completed the prior double-blind stud...
Location
Multiple Locations
12-Week, Double-Blind, Placebo-Controlled, Randomized Study of the Efficacy of 40 mg/Day KW-6002 in Parkinson's Disease Patients on Levodopa/Carbidopa
PHASE212-week, double-blind, placebo-controlled, multicenter, randomized study de...
Location
Contact Kyowa Pharmacuetical Inc.
Long Term Study of Istradefylline in Subjects With Moderate to Severe Parkinson's Disease
PHASE3This is a Phase 3, 52-week, open-label, flexible-dose, multinational, multi...
An Extension of Istradefylline in North American Parkinson's Disease Patients Who Have Completed Study 6002-INT-001
PHASE3This is an, open-label, long-term safety extension for patients in North Am...
Location
Kyowa Pharmaceutical Inc.